This Article Full Text Full Text (PDF) All Versions of this Article: 40/1/67    most recent 01.HYP.0000022805.11288.7Fv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, T.-M. Articles by Tsai, C.-H. Search for Related Content PubMed PubMed Citation Articles by Lee, T.-M. Articles by Tsai, C.-H. Related Collections Lipids Risk Factors Clinical Studies

(Hypertension. 2002;40:67.)
© 2002 American Heart Association, Inc.

Scientific Contributions

Effect of Pravastatin on Proteinuria in Patients With Well-Controlled Hypertension

From the Departments of Internal Medicine (T.-M.L.) and Surgery (C.-H.T.), Cardiology Section, National Taiwan University Hospital, Taipei; and the Department of Clinical Pharmacy, College of Medicine, National Cheng Kung University (S.-F.S.), Tainan, Taiwan.

Correspondence to Dr Tsung-Ming Lee, Department of Internal Medicine, Cardiology Section, National Taiwan University Hospital, 7, Chung-Shan S. RD, Taipei, Taiwan, 10002. E-mail tmlee{at}ha.mc.ntu.edu.tw

Proteinuria is an important risk factor for cardiovascular and renal morbidity and mortality. The effects of 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitor (statin) therapy on proteinuria in normolipidemic patients with well-controlled hypertension have not been studied. A total of 63 normolipidemic (total cholesterol <240 mg/dL) and proteinuric (300 to 3000 mg/d) patients with well-controlled blood pressure (<140/90 mm Hg) were randomized to receive either placebo (n=32) or pravastatin (10 mg/d; n=31) after a 3-month placebo period. Pravastatin lowered proteinuria after 6 months by 54% (P<0.0001). Creatinine clearance was stable throughout the study in the 2 groups. Despite unchanged plasma endothelin-1 levels throughout the study, urinary excretion of the peptide was decreased and significantly correlated with improvement in urinary protein excretion in pravastatin-treated patients (r=0.64, P=0.001). The urinary excretion of retinol-binding protein decreased after pravastatin administration, probably reflecting an improvement in tubular function. In contrast, the urinary excretion of IgG did not change significantly throughout the study in either group. Multivariate analysis revealed that proteinuria was only significantly correlated with statin use (P<0.0001, R²= 0.66). Linear regression analysis in the statin-treated group did not show any correlation between changes in lipid profiles and proteinuria regression. Thus, in addition to their primary function of antilipidemia, the addition of pravastatin to treatment for well-controlled hypertension may have an additive effect on reducing proteinuria independent of hemodynamics and lipid-lowering effects, possibly through inhibiting renal endothelin-1 synthesis and improving tubular function.

Key Words: receptors, angiotensin II • endothelin-1 • hypertension, chronic • statins • proteinuria

This article has been cited by other articles:

				T.-M. Lee, M.-S. Lin, and N.-C. Chang Effect of pravastatin on sympathetic reinnervation in postinfarcted rats Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3617 - H3626. [Abstract] [Full Text] [PDF]

				R. Agarwal Effects of Statins on Renal Function Mayo Clin. Proc., November 1, 2007; 82(11): 1381 - 1390. [Abstract] [Full Text] [PDF]

				L. Romayne Kurukulasuriya, G. Athappan, G. Saab, A. Whaley Connell, and J. R. Sowers Review: HMG CoA reductase inhibitors and renoprotection: the weight of the evidence Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 49 - 59. [Abstract] [PDF]

				M. Franciosi, F. Pellegrini, M. Sacco, G. De Berardis, M. C.E. Rossi, G. F.M. Strippoli, M. Belfiglio, G. Tognoni, M. Valentini, A. Nicolucci, et al. Identifying Patients at Risk for Microalbuminuria via Interaction of the Components of the Metabolic Syndrome: A Cross-Sectional Analytic Study Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 984 - 991. [Abstract] [Full Text] [PDF]

				A. Gianella, E. Nobili, M. Abbate, C. Zoja, P. Gelosa, L. Mussoni, S. Bellosta, M. Canavesi, D. Rottoli, U. Guerrini, et al. Rosuvastatin Treatment Prevents Progressive Kidney Inflammation and Fibrosis in Stroke-Prone Rats Am. J. Pathol., April 1, 2007; 170(4): 1165 - 1177. [Abstract] [Full Text] [PDF]

				T.-M. Lee, M.-S. Lin, C.-H. Tsai, C.-L. Huang, and N.-C. Chang Effects of sulfonylureas on left ventricular mass in type 2 diabetic patients Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H608 - H613. [Abstract] [Full Text] [PDF]

				M. E. Molitch Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1090 - 1099. [Abstract] [Full Text] [PDF]

				K. Douglas, P. G. O'Malley, and J. L. Jackson Meta-Analysis: The Effect of Statins on Albuminuria Ann Intern Med, July 18, 2006; 145(2): 117 - 124. [Abstract] [Full Text] [PDF]

				S. Sandhu, N. Wiebe, L. F. Fried, and M. Tonelli Statins for Improving Renal Outcomes: A Meta-Analysis J. Am. Soc. Nephrol., July 1, 2006; 17(7): 2006 - 2016. [Abstract] [Full Text] [PDF]

				P. W. G. du Buf-Vereijken and J. F. M. Wetzels Treatment-related changes in urinary excretion of high and low molecular weight proteins in patients with idiopathic membranous nephropathy and renal insufficiency Nephrol. Dial. Transplant., February 1, 2006; 21(2): 389 - 396. [Abstract] [Full Text] [PDF]

				A. Rashidi, M. Rahman, M. Tonelli, C. Isles, T. Craven, C. Furberg, A. Tonkin, M. A. Pfeffer, J. Shepherd, S. M. Cobbe, et al. Letter Regarding Article by Tonelli et al, "Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease" * Response Circulation, January 31, 2006; 113(4): e59 - e60. [Full Text] [PDF]

				B. Bussolati, M. C. Deregibus, V. Fonsato, S. Doublier, T. Spatola, S. Procida, F. Di Carlo, and G. Camussi Statins Prevent Oxidized LDL-Induced Injury of Glomerular Podocytes by Activating the Phosphatidylinositol 3-Kinase/AKT-Signaling Pathway J. Am. Soc. Nephrol., July 1, 2005; 16(7): 1936 - 1947. [Abstract] [Full Text] [PDF]

				E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508. [Full Text] [PDF]

				T.-M. Lee, M.-S. Lin, T.-F. Chou, and N.-C. Chang Effect of simvastatin on left ventricular mass in hypercholesterolemic rabbits Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1352 - H1358. [Abstract] [Full Text] [PDF]

				L. Vogt, G. Navis, and D. de Zeeuw Individual Titration for Maximal Blockade of the Renin-Angiotensin System in Proteinuric Patients: A Feasible Strategy? J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S53 - S57. [Abstract] [Full Text] [PDF]

				V. L.M. Esnault, A. Ekhlas, C. Delcroix, M.-G. Moutel, and J.-M. Nguyen Diuretic and Enhanced Sodium Restriction Results in Improved Antiproteinuric Response to RAS Blocking Agents J. Am. Soc. Nephrol., February 1, 2005; 16(2): 474 - 481. [Abstract] [Full Text] [PDF]

				M.-S. Zhou, E. A. Jaimes, and L. Raij Atorvastatin Prevents End-Organ Injury in Salt-Sensitive Hypertension: Role of eNOS and Oxidant Stress Hypertension, August 1, 2004; 44(2): 186 - 190. [Abstract] [Full Text] [PDF]

				N.D. Vaziri and K.H. Liang Acyl-Coenzyme A:Cholesterol Acyltransferase Inhibition Ameliorates Proteinuria, Hyperlipidemia, Lecithin-Cholesterol Acyltransferase, SRB-1, and Low-Denisty Lipoprotein Receptor Deficiencies in Nephrotic Syndrome Circulation, July 27, 2004; 110(4): 419 - 425. [Abstract] [Full Text] [PDF]

				C. Olianti, A. Imperiale, M. Materassi, D. Seracini, R. Ienuso, M. Tommasi, A. Pupi, and G. La Cava Urinary endothelin-1 excretion according to morpho-functional damage lateralization in reflux nephropathy Nephrol. Dial. Transplant., July 1, 2004; 19(7): 1774 - 1778. [Abstract] [Full Text] [PDF]

				N. M Maisch and K. K Pezzillo HMG-CoA Reductase Inhibitors for the Prevention of Nephropathy Ann. Pharmacother., February 1, 2004; 38(2): 342 - 345. [Abstract] [Full Text] [PDF]

				L. Vogt, G. D. Laverman, R. P. F. Dullaart, and G. Navis Lipid management in the proteinuric patient: do not overlook the importance of proteinuria reduction Nephrol. Dial. Transplant., January 1, 2004; 19(1): 5 - 8. [Full Text] [PDF]

				F. Youssef, P. Gupta, A. M. Seifalian, F. Myint, D. P. Mikhailidis, and G. Hamilton The Effect of Short-Term Treatment with Simvastatin on Renal Function in Patients with Peripheral Arterial Disease Angiology, January 1, 2004; 55(1): 53 - 62. [Abstract] [PDF]

				W. A. Wilmer, B. H. Rovin, C. J. Hebert, S. V. Rao, K. Kumor, and L. A. Hebert Management of Glomerular Proteinuria: A Commentary J. Am. Soc. Nephrol., December 1, 2003; 14(12): 3217 - 3232. [Abstract] [Full Text] [PDF]

				L. Solano-Gallego, A. Rodriguez, L. Iniesta, M. Arboix, M. Portus, and J. Alberola Detection of Anti-Leishmania Immunoglobulin G Antibodies in Urine Specimens of Dogs with Leishmaniasis Clin. Vaccine Immunol., September 1, 2003; 10(5): 849 - 855. [Abstract] [Full Text] [PDF]